Biotronik has announced the milestone achievement of 100,000 implanted single-chamber implantable cardioverter-defibrillators (ICDs) equipped with DX Technology.
Since the introduction of the technology in 2009, clinicians in more than 80 countries across all continents use DX ICDs.
“Reaching this significant milestone, Biotronik stands as a proud pioneer and partner in cardiac rhythm management. Our commitment to quality and focus on innovation sets us apart, allowing us to introduce meaningful innovations in the market, such as DX Technology, that make a real difference in patients’ lives,” Andreas Hecker, president CRM/EP at Biotronik, comments. “This milestone demonstrates our collective efforts and dedication to making a positive difference and helps us define a new standard in patient care.”
DX Technology is available as a single-lead ICD system equipped with a floating atrial dipole and helps monitor AF burden over time so that clinicians can intervene when needed, react to changes in patient status and optimize patient treatment.
“We are deeply grateful for the trust we’ve received from the medical community. We develop solutions to ease physicians’ workloads and improve patient care through holistic and connected approaches. Our innovations are rooted in trustworthy customer relations, feedback and our extensive expertise in cardiac device implants and leads,” says David Hayes, chief medical officer, Biotronik. “With this impressive milestone and the extensive clinical evidence, DX Technology has proven itself, and I am confident that we will reach more milestones such as this in the years to come.”
